Clinical Trial Update: Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bicalutamide with or without the Akt inhibitor MK-2206 in previously treated prostate cancer has posted results. The update covers the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• MK-2206 (MK-2206)
• bicalutamide (bicalutamide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Prostate Carcinoma, Stage I Prostate Cancer AJCC v7 | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2019-12-05